RTW Venture Fund welcomes IPO of portfolio company CinCor Pharma

view original post

StockMarketWire.com – Investment group RTW Venture Fund welcomed news that portfolio company CinCor Pharma had priced an upsized $193.6 million initial public offering in the US.

CinCor was a clinical-stage biopharmaceutical company developing treatments for cardio-renal diseases.

CinCor’s IPO raised $193.6 million by offering about 12.1 million shares at $16.00 each On the first day of trading, its share price remained flat to close at $16.00 per share.

Story provided by StockMarketWire.com